8-K current report · filed Nov 2, 2026

Xeris Biopharma Holdings, Inc. (XERS) 8-K Current Report: November 2, 2026

Item 5.02Item 7.01Item EX-99.1XERS overview

Short answer

Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded from 8 to 9 directors, adding Menassie Taddese effective November 2, 2026.

Xeris Biopharma Holdings, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Board expanded from 8 to 9 directors, adding Menassie Taddese effective November 2, 2026
  • Taddese brings Pfizer and Viatris emerging-markets and finance experience, potentially supporting international growth strategy
  • Audit Committee appointment, with Nasdaq and Exchange Act independence qualification
  • Initial equity award valued at approximately $450,000, creating shareholder dilution and onboarding compensation
  • Future annual equity grants targeted at approximately $300,000, vesting subject to continued board service

Item 7.01 · Regulation FD Disclosure

  • Taddese appointed to Xeris Biopharma’s Board of Directors
  • Board refresh may influence governance, strategic oversight and shareholder confidence
  • Appointment details and rationale provided in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Menassie M. Taddese appointed director effective November 2, 2026
  • Audit Committee appointment strengthens board financial oversight and governance expertise
  • Former Viatris Emerging Markets president, overseeing an approximately $3 billion business across more than 125 markets
  • Board addition supports commercial portfolio growth and advancement of Phase 3-ready XP-8121

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Xeris Biopharma Holdings, Inc. 8-K filings

Get the next XERS 8-K as it lands

Follow XERS for push alerts, or ask the research agent what this filing means.